Assessment of inter-regulation of TDP-43, FUS and the androgen receptor in prostate cancer cells by Högman, Sini
  
 
 
 
ASSESSMENT OF INTER-REGULATION OF 
TDP-43, FUS AND THE ANDROGEN 
RECEPTOR IN PROSTATE CANCER CELLS 
Sini Högman 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Bachelor’s Thesis 
May 2018 
Degree Programme in  
Environmental Engineering  
Laboratory Engineering 
 
  
ABSTRACT 
Tampereen ammattikorkeakoulu 
Tampere University of Applied Sciences 
Degree Programme in Environmental Engineering 
Laboratory Engineering 
 
HÖGMAN, SINI:  
Assessment of Inter-Regulation of TDP-43, FUS and the Androgen Receptor in Prostate 
Cancer Cells 
 
Bachelor's Thesis 42 pages 
May 2018 
Prostate cancer is common in many western countries. Advanced prostate cancer is 
treated with hormonal therapy to suppress the cancer-promoting androgen and androgen 
receptor (AR) function. Incurable castration resistant prostate cancer (CRPC) emerges 
after therapy. Understanding of mechanisms leading into castration resistance is needed 
to discover treatment methods. 
 
The purpose of this thesis was to determine how changing the levels of the three proteins 
alters the levels of each individual protein. The objective was to provide a preliminary 
study of their inter-regulation and to assess the required experimental methods. 
 
Changes in the regulation of two proteins, TDP-43 and FUS, in prostate cancer cells were 
studied in this thesis. Their inter-regulation affected by cell line AR status was deter-
mined. The genes responsible for the proteins and AR were silenced and overexpressed 
with transfections in two prostate cancer cell lines. Changes in protein levels were then 
assessed with Western Blotting.  
 
Some evidence was found of inter-regulation linked to sample AR status. In the cells with 
high AR expression, FUS overexpression increased TDP-43 levels and silencing TDP-43 
decreased FUS levels. No alterations occurred in cells with low AR expression. This study 
forms the groundwork of further experimentation that is required to confirm and further 
analyse these results. 
Key words: prostate cancer, TDP-43, FUS, androgen receptor, CRPC 
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Eturauhassyöpä on yleisin syöpä ja toiseksi yleisin syöpäkuolemien aiheuttaja monissa 
länsimaissa. Pitkälle edennyttä syöpää hoidetaan hormoniterapialla, joka vaimentaa 
eturauhassyövälle olennaista androgeenireseptorin (AR) signalointia. Onnistuneen hor-
moniterapian jälkeen eturauhassyöpä kuitenkin uusiutuu aggressiivisena, hormonitera-
pialle resistanttina muotona (kastraatioresistantti eturauhassyöpä, CRPC), johon ei tällä 
hetkellä ole toimivaa hoitokeinoa. CRPC:ä estävien ja hoitavien keinojen löytämiseksi 
ymmärrystä kastraatioresistanssiin johtavista molekyylibiologisista mekanismeista on 
lisättävä. 
 
Tässä opinnäytetyössä tutkittiin tarkemmin viimeaikaisia tutkimustuloksia proteiinitason 
muutoksista eturauhassyövän taudinkehityksen aikana. Työ keskittyi kahden syövän 
etenemiselle merkittäväksi havaituksi, proteiinitasolla vastakkaisiin suuntiin säädellyn 
RNA;ta sitovan proteiiniin, TDP-43:n ja FUS:n. Opinnäytetyössä selvitettiin näiden pro-
teiinien proteiinitason mahdollista yhteissäätelyä toisiinsa nähden ja AR-tasojen sekä 
eturauhassyöpäsolulinjojen AR-statuksen vaikutusta siihen. 
 
Opinnäytetyön tavoite oli tuottaa esikatsaus näiden kolmen proteiinin mahdollisesta 
yhteissäätelystä ja testata tutkimuksessa käytettävien protokollien sekä välineiden toimi-
vuus. Tutkimuksen tarkoitus oli määrittää, miten kolmea proteiinia tuottavien geenien 
hiljentäminen sekä yliekspressio vaikuttavat muiden proteiinien tasoihin eturau-
hassyöpäsoluissa. 
 
Proteiineja tuottavat geenit hiljennettiin ja yliekspressoitiin siRNA- sekä plasmiditrans-
fektioilla eturauhassyöpäsolulinjoissa LNCaP ja PC-3, joiden AR-status eroaa toisistaan. 
Transfektioita seuraavat muutokset kolmen proteiinin tasoissa soluissa määritettiin West-
ern Blottingilla. 
 
Opinnäytetyön tulokset antoivat muun muassa viitteitä mahdollisesta TDP-43:n ja FUS:n 
yhteissäätelystä tavalla, joka liittyy eturauhassyöpäsolujen AR-statukseen. Korkeaa AR-
statusta mallintavissa LNCaP-soluissa FUS:n yliekspressoiminen johti TDP-43-tason 
nousuun, kun taas TDP-43:n hiljentäminen FUS-tason laskuun. Matalan AR-ekspression 
PC-3-soluissa ei havaittu samaa vaikutusta. Tutkimustulosten varmistaminen ja syvempi 
tutkiminen kuitenkin vaativat kokeiden uusimista. Opinnäytetyön tulokset luovat pohjan 
jatkotutkimuksille aiheeseen. 
Asiasanat: eturauhassyöpä, TDP-43, FUS, androgeenireseptori, CRPC  
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ABBREVIATIONS AND TERMS 
 
 
2-DE two-dimensional gel electrophoresis 
Ab   antibody 
ACO2   aconitase 2 
ADT  androgen deprivation therapy 
Ag   antigen 
ALS amyotrophic lateral sclerosis  
AR androgen receptor 
ARE androgen response element 
BPH benign prostatic hyperplasia 
BSA   bovine serum albumin 
CRPC castration resistant prostate cancer 
DBD DNA binding domain  
DHEA dehydroepiandrosterone 
DHT   dihydrotestosterone 
dsDNA double-stranded DNA 
ECL enhanced chemiluminescence 
ELISA enzyme-linked immunosorbent assay 
ERG erythroblast related gene 
ETS erythroblast transformation-specific related gene  
FBS   fetal bovine serum 
FEV fifth Ewing variant 
FTLD frontotemporal lobar degeneration 
FUS fused in sarcoma 
HGPIN high grade prostatic intraepithelial neoplasia 
HRP   horseradish peroxide 
IEF  isoelectric focusing 
IP immunoprecipitation 
LB   lysogeny broth 
LBD   ligand binding domain 
miRNA microRNA 
mRNA   messenger RNA 
MudPIT multidimensional protein identification technology 
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NTD amino terminal domain 
p53 tumour suppressor phosphoprotein 53 
PBS   phosphate-buffered saline 
PCa   prostate cancer / prostate adenocarcinoma 
pre-mRNA precursor mRNA 
PSA prostate specific antigen 
PTM   post-translational modification 
RBPs RNA-binding proteins 
RISC RNA-induced silencing complex 
RNAi RNA interference 
SBMA Kennedy’s disease or spinal and bulbar muscular atrophy  
SDS-PAGE sodium dodecyl sulphate polyacrylamide gel electrophoresis 
SV   splice variant 
TARDBP the gene coding for TDP-43 
TBS   triton-buffered saline 
TDP-43 transactive response binding protein of 43 kDa  
TRIM16 tripartite motif-containing protein 16 
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1 INTRODUCTION 
 
 
Prostate cancer is the second leading cause of cancer deaths and the most common male 
cancer in many western countries (Siegel, Miller & Jemal 2017). Prostate cancer progres-
sion is dependent on androgens and the signalling of the androgen receptor (AR) in pros-
tate cells. Advanced prostate cancer is treated with hormonal androgen deprivation ther-
apy (ADT) to suppress the AR signalling. (Watson, Arora & Sawyers 2015) 
 
However, castration-resistant prostate cancer (CRPC) emerging after ADT treatment is 
lethal, aggressive and at the moment incurable. Better understanding of the molecular 
mechanics into castration resistance is needed to find therapeutic methods capable of pre-
venting and treating CRPC in the future. (Shen & Abate-Shen 2010) 
 
In this thesis, carried out at the Molecular Biology of Prostate Cancer Group at the Uni-
versity of Tampere Faculty of Medicine and Life Sciences, and supervised by Ph.D. 
Leena Latonen, changes at the protein level during prostate cancer progression are stud-
ied. Two proteins showing dysregulation at the protein level of prostate cancer and CRPC, 
transactive response binding protein of 43 kDa (TDP-43) and fused in sarcoma (FUS) are 
the focus of the thesis. Their interactions with AR and possible inter-regulation are as-
sessed. 
 
Silencing and overexpression of the genes responsible for TDP-43, FUS and AR are car-
ried out with transfections. Two prostate cancer cell lines expressing AR differently are 
used. The following changes in the levels of the three proteins are assessed with Western 
Blotting.  
 
The purpose of the thesis is to determine how changing the levels of TDP-43, FUS and 
AR affects the levels of the other proteins in two prostate cancer cell lines that express 
AR differently. The objective of the study is to assess the inter-regulation of the proteins 
in prostate cancer progression and to test the protocols and reagents involved in the study 
for further research. 
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2 THEORETICAL BACKGROUND 
 
 
2.1 Prostate Cancer 
 
Prostate carcinoma is cancer, malignant growth resulting in tumour formation, occurring 
in the prostate. Prostate cancer has a strong correlation with high age, mean age of diag-
nosis being 66 years (American Cancer Society 2018). It causes problems in urinating, 
erection and ejaculation, as well as discomfort or pain, bowel problems and fatigue that 
lower life quality. Prostate cancer can also be symptomless and continue unnoticed for 
long. Ultimately in advanced cancer, painful bone metastases and death are a cause of 
concern for patients. (Cancer Treatment Centers of America 2016) 
 
The normal prostate gland is a walnut sized male gland located at the base of the bladder, 
surrounding the urethra (Shen & Abate-Shen 2010). Its function is to produce prostatic 
fluid into seminal fluid and to aid in ejaculation by contracting. Prostatic fluid contains 
high amounts of citrate and zinc which maintain an electrochemical balance, and enzymes 
such as prostate specific antigen (PSA). (Costello & Franklin 2009) 
 
The prostate has a zonal architecture, shown in figure 1 together with the prostate loca-
tion. As shown in the figure, the prostate is comprised of the central zone, the fibromus-
cular zone or stroma, the transition zone, the peripheral zone and the periurethral zone. 
The outermost peripheral zone is where most prostate cancers and prostatitis originate, 
whereas the transition zone is the most common site of benign prostate hyperplasia 
(BPH). (Aaron, Franco & Hayward 2016)  
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FIGURE 1. Anatomical location (left) and zones (right) of the prostate, cross-section. 1: 
central zone, 2: fibromuscular zone, 3: transition zone, 4: peripheral zone and 5: periure-
thral zone (Edited from Hoffmann M. 2008 (left) and De Marzo et al. 2007 (right))  
 
Prostatitis and BPH are benign forms of prostate problems that cause prostate enlarge-
ment. Prostatitis, prostate inflammation, is usually caused by bacterial infection and is 
curable. Causes of BPH are more complex, and its symptoms can be eased but not com-
pletely cured. (Collins, Stafford, O'Leary & Barry 1999) 
 
Prostate tissue is comprised of luminal and basal epithelial cells surrounded by stromal 
tissue. There is also a rare cell type, neuroendocrine cells, present in the prostate tissue in 
few numbers. Epithelial cells are the sheet-forming cells that form exterior surfaces and 
surround glands and cavities of the body. The epithelial cells of the prostate are organ-
surrounding glandular cells that produce secretions. (Schrecengost & Knudsen 2013) 
 
Prostate cancer is preceded by high-grade prostatic intraepithelial neoplasia (HGPIN) 
which is diagnosed by biopsy. HGPIN causes multifocal lesions with abnormal growth 
and differentiation of luminal cells as well as reduction of basal cells. Benign prostate 
hyperplasia and prostatitis in turn are not precursors of cancer. (Schrecengost & Knudsen 
2013) Figure 2 illustrates how the prostatic epithelial tissue is altered along the develop-
ment of cancer from HGPIN to metastatic cancer.  
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Figure 2. Changes in the prostate epithelium during the development of prostate cancer 
(Edited from Shen & Abate-Shen 2010) 
 
Prostatic abnormalities lead to an increase in PSA levels in serum, which is used for di-
agnosis. PSA is a serine protease enzyme which liquefies seminal fluid. As a result of any 
prostate disruption, it is released into blood. Unfortunately, PSA testing cannot differen-
tiate between benign and malign prostate conditions. This has lead to the problem of 
overtreatment and inability to direct treatment to patients most in need of it. (Pérez-Ibave, 
Burciaga-Flores & Elizondo-Riojas 2018) 
 
Patients with increased PSA levels undergo biopsy, where tissue samples are gathered 
and histopathologically examined under the microscope. The tissue is graded according 
to the Gleason score method to evaluate the severity of the abnormalities. An evaluation 
of five cellular pattern categories is performed and the grades combined to get a score of 
2 to 10, where a score of 7 to 10 indicates aggressive cancer. (Humphrey 2004) 
 
Prostate cancers are mostly adenocarcinomas which originate in glandular epithelial cells 
(Hartmann & Friess 2017). Characteristics of prostate cancer include a luminal phenotype 
and bone metastasis. Prostate cancer is dependent upon circulating androgens such as 
testosterone and their action occurring through the hormonal androgen receptor (AR) in 
prostate cells. (Shen & Abate-Shen 2010) 
 
Prostate cancer shows a luminal phenotype that is promoted by AR. Luminal epithelial 
cells, which have high AR expression, are increased and basal epithelial cells reduced in 
prostate cancer. This change is already seen during HGPIN formation. The abundance of 
luminal cells could be due to basal cells differentiating into luminal cells in cancer. (Xin 
2013)  
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Primary prostate cancer, localised only to its primary site without metastasis, is treated 
with prostatectomy, chemotherapy and radiotherapy. Prostatectomy is the surgical re-
moval of the tumour or the whole prostate. Radiotherapy aims to destroy cancer cells by 
high-energy radiation. (Zhen & Zhao 2013) 
 
Advanced prostate cancer refers to cancer that is incurable by surgery or radiation, and 
can be metastatic or non-metastatic. Metastasis, a feature of advanced cancer, means the 
spread of cancer to a secondary site in the body. Prostate cancer forms metastases into 
bone which are bone-forming, osteoblastic, in contrast to osteolytic, bone-consuming me-
tastases formed by many other cancers. (Logothetis & Lin 2005) 
 
Advanced prostate cancer is treated with hormonal ADT which aims to suppress the pres-
ence of androgens in the body. ADT is achieved through either surgical or chemical cas-
tration. Chemical castration is induced with antiandrogens such as bicalutamide or gon-
adotropin-releasing hormone (gnRH) agonists or antagonists. In combined androgen 
blockade these medications are used together for more efficient AR suppression. (Wat-
son, Arora & Sawyers 2015) 
 
Androgen deprivation therapy however causes side effects that lower the life quality of 
patients (Mohile et al. 2009). Moreover, a recurring, lethal form of prostate cancer 
emerges in close to all cases after ADT with rising PSA levels and symptoms. In CRPC, 
cancer cells have acquired resistance to hormonal therapy, bypassing the suppression of 
androgens and AR signalling. (Hotte & Saad 2010) Although the survival estimate of 
patients with CRPC has significantly improved, no completely curative treatment is avail-
able. To find therapeutic methods capable of treating CRPC, the molecular mechanisms 
underlying progression into castration resistance must be elucidated. (Wong, Fer-
raldeschi, Attard & de Bono 2014) 
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2.1.1 Androgen Receptor 
 
Androgen receptor (AR) is the nuclear steroid hormone receptor responsible for mediat-
ing the effect of androgens on the prostate. Formation and development of the prostate, 
as well as prostate cancer progression, are dependent upon it. (Lonergan & Tindall 2011) 
Figure 3 illustrates the structure and location of the AR gene located on position 11 to 12 
on the longer arm of the chromosome X (q11-12). It also shows the structural parts of the 
AR protein: NTD, the amino terminal domain, DBD, the DNA binding domain and LBD, 
the ligand binding domain. 
 
 
FIGURE 3. Chromosomal location (Xq11-12) and structure of the AR gene (above). 
Structure of the AR protein (below), where NTD is the amino terminal domain, DBD the 
DNA binding domain and LBD the ligand binding domain (Edited from Lonergan & Tin-
dall 2011) 
 
Androgens are steroid hormones produced by testes and the adrenal gland. They regulate 
the development of male characteristics. Testosterone is the most abundant one in the 
body and is metabolized into more potent dihydrotestosterone (DHT). In the prostate, 
DHT has a higher affinity for AR and therefore is effective at lower concentrations. (Wat-
son et al. 2015) 
 
The effects of androgens are mediated through the transcriptional activity of AR. Andro-
gens bind to the AR ligand binding domain (LBD) and cause AR to bind to androgen 
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response elements (AREs) in DNA. AR then transcriptionally activates androgen-targeted 
genes such as the PSA gene. (Xu et al. 2009) 
 
The dependence of the prostate on androgens can be seen as prostate cell apoptosis fol-
lowing ADT. However, androgen-dependent prostate cell lines do not undergo apoptosis 
after hormone depletion but only cease division and growth. This indicates that apoptosis 
signal requires induction that the prostatic stroma normally provides. (Shen & Abate-
Shen 2010) 
 
One of AR’s functions in normal prostate tissue is to inhibit proliferation. In cancer AR 
instead inhibits basal cell proliferation and promotes growth of luminal cells which have 
high AR expression. This causes the strongly luminal phenotype of prostate cancer. AR 
also is the metastasis-promoting factor in prostate cancer. (Schrecengost & Knudsen 
2013)  
 
 
2.1.2 Reactivation of AR Signalling in CRPC 
 
Many theories attempt to explain how prostate cancer cells are able to maintain and reac-
tivate AR signalling in castration resistance. AR reactivation can occur through AR am-
plification and mutations, AR protein overexpression, splice variants (SVs), posttransla-
tional modifications (PTMs) and prostatic intratumoural androgen synthesis. (Watson et 
al. 2015) 
 
Intratumoural androgen synthesis refers to AR signalling sustained by trace amounts of 
residual androgens and other steroid hormones remaining after castration. For example, 
dehydroepiandrosterone (DHEA) produced by the adrenal gland is a metabolic interme-
diate of testosterone. DHEA is a weak androgen, meaning that it only mildly stimulates 
AR in high concentrations. Normally adrenal hormones are only a minor source of tes-
tosterone. About 90 per cent of all testosterone is produced by the testes. (Cai & Balk 
2011) 
 
After ADT, the weak adrenal androgens become an increasing source of testosterone that 
continue to maintain prostate cancer. In CRPC, DHT levels remain high or are even in-
creased compared to normal tissue. The enzymes required for synthesis of testosterone 
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and DHT from weak androgens show increased expression in CRPC as well. (Montgom-
ery et al. 2008) 
 
The prostate stroma normally secretes paracrine growth factors, maintaining the hormo-
nal regulation of androgen production. With intratumoural androgen synthesis, a shift to 
an autocrine, self-controlled, production by the cancerous epithelial cells is observed. 
This is coupled with overexpression of paracrine growth factors. (Marques et al. 2010) 
 
AR amplifications or gains increase AR copy number resulting in AR protein overexpres-
sion. Overexpression sensitizes prostate cells to androgens. Amplification is found in 
around 30 per cent of CRPC cases. (Edwards et al. 2003) AR mutations, present in around 
10 to 30 per cent of recurring cancer cases, are mostly gain-of-function point mutations 
produced by selection after ADT. Treatment with androgens causes selective pressure, 
where mutations that allow survival despite AR suppression are favoured. (Waltering, 
Urbanucci & Visakorpi 2012) 
 
Mutations are observed mostly in the AR LBD occurring in the codons 736 to 771. LBD 
mutations can increase sensitivity to AR or reduce specificity of ligand binding, allowing 
activation by other ligands than androgens. (Eisermann et al. 2013) They are mostly point 
mutations which alter one nucleotide base in DNA (Hartwell et al. 2016, 208). One point 
mutation reducing ligand specificity present in CRPC was discovered in AR codon 877 
in 1995 (Taplin et al.). It is also present in the AR expressing prostate cancer cell line 
LNCaP. This mutation, referred to as T877A, generates AR that can be activated by oes-
trogen, progesterone and the anti-androgen flutamide. Cells exhibiting this mutation are 
not inhibited but in turn activated by anti-androgens. T877A promotes survival and 
growth of cancer cells and resistance to apoptosis. (Sun et al. 2006) 
 
Proteomic and transcriptional causes of castration resistance include splice variants and 
post-translational modifications. Post-translational modifications (PTMs) are modifica-
tions that alter proteins after their translation. PTMs of AR include methylation, ubiq-
uitylation and phosphorylation of the protein. Splice variants (SVs) are different forms of 
proteins created by alternative splicing. Introns, parts of genes unused for RNA synthesis, 
can be removed in different ways to produce multiple RNA products from one gene. 
(Hartwell et al. 2016, 272, 280) Splice variants of AR may provide alternative transcrip-
tional pathways for prostate cancer. They promote AR activation through a variety of 
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mechanisms, such as increasing transcriptional activity or binding to DNA. (Schrecengost 
& Knudsen 2013) 
 
 
2.2 The Proteome of Prostate Cancer 
 
Proteomics is the study of the proteome and individual proteins. The proteome refers to 
the combination of all proteins in a biological entity such as a cell. It consists of the final 
products of all active genes at a given time. Proteomic research is concerned not only in 
the protein content but also structure, structural modifications, activity, interactions with 
other proteins and molecules as well as localisation in cells. (Zhang et al. 2013) 
 
Figure 4 illustrates the stages of how the information of DNA is activated through pro-
teins, and the terms involved. DNA is transcribed into precursor mRNA (pre-mRNA), 
which is processed into messenger RNA (mRNA) by removing introns in splicing and 
adding protective and regulatory features. mRNA is translated into proteins which un-
dergo among all post-translational modifications to form the final gene products. (Hart-
well et al. 2016, 264–280)  
 
 
FIGURE 4. The flow of genetic information from the genome to the proteome, and the 
related terms. (Edited from Graves & Haystead 2002) 
 
The messenger RNA content of cells, referred to as the transcriptome, and the genome do 
not always directly translate to the proteome. Therefore, assessing molecular mechanics 
at the genomic and transcriptomic level is not enough to elucidate the whole picture of 
the molecular biology of cancer and other disease. Proteins are not only regulated at the 
transcriptome level. Their expression does not always reflect the levels of their corre-
sponding mRNA. This is why studies of the proteome of cancer are needed to understand 
the disease. (Iglesias-Gato et al. 2016) 
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Different products from the same gene can occur at the level of transcription, translation 
or modifications of synthesized mRNA and proteins. For example, alternative splicing of 
RNA and post-translational modifications applied after protein translation create different 
proteins from the same genes. Protein modifications are important features of diseases 
and the mechanisms underlying them. (Graves & Haystead 2002) Proteins consist of 20 
amino acids which provide greater diversity than the four nucleotide bases that determine 
DNA sequence (Herrmann, Liotta & Petricoin III 2001). 
 
The proteome is a complex set of biomolecules under constant change stemming from its 
environment. Studying the proteome involves examining the protein assembly and its 
components in their immediate and momentarily surroundings. Changes in the cell envi-
ronment are reflected on the proteome. Proteins can be modified, re-localised or degraded 
in response to various stimuli. (Harper & Bennett 2016) 
 
Development of disease such as cancer affects the protein content of tissues. This can be 
used to find new diagnostic methods. (Gallego & Gavin 2007) Proteins are also the pri-
mary targets of validated drugs, and contain binding sites related to disease mechanics 
where the drug molecules can interact (Bull & Doig 2015). Many biomarkers, indicators 
of biological conditions used to diagnose disease, are proteins (Herrmann et al. 2001). 
 
Dysregulation in the expression of proteins related to growth, survival and function of 
normal cells promotes cancer. Dysregulation involves changes in protein expression level 
or misguided production of proteins. (The Human Protein Atlas n.d.) Structural alteration 
of proteins such as misfolding can cause protein aggregation in cells leading to various 
diseases. If misfolding occurs in proteins that have functions in growth and differentia-
tion, cancer can be the result. (Chaudhuri & Paul 2006) For example, inactivation of the 
gene producing the tumour suppressor phosphoprotein 53 (p53) is present in more than 
half of human cancers (Nikolova et al. 2000).  
 
The proteome of cells is significantly altered during prostate cancer. Genomic events such 
as DNA methylation, mutations and gene copy number alterations influence mRNA but 
not always the proteome in prostate cancer. Most proteins match levels of their corre-
sponding mRNA in prostate cancer, but the correlation is lower in CRPC. The proteomic 
profiles of BPH, primary prostate cancer and CRPC are very distinctive. Comparing the 
proteomic profiles with each other can reveal molecular level changes occurring with 
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cancer initiation, progression and development into castration resistance. (Latonen et al. 
2018) 
 
Some proteins are dysregulated at the protein level of prostate cancer. Among the ones 
dysregulated at the protein level are TDP-43 and FUS, RNA-binding proteins (RBPs) 
similar in structure and function.  Primary prostate cancer with low AR expression and 
CRPC with high AR expression show distinct TDP-43 and FUS protein expression pro-
files with a negative correlation with each other. The expression data suggests a signifi-
cance of TDP-43 and FUS in CRPC that is linked to the AR level of the cancer cells. 
(Latonen 2017) 
 
Moreover, TDP-43 and FUS have previously been linked to each other in neurodegener-
ative disease. In amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degenera-
tion (FTLD), mutated and misfolded forms of these proteins accumulate in neurons into 
inclusions that deteriorate nervous system function. TDP-43 and FUS proteinopathies is 
the nomenclature for these conditions. (Da Cruz & Cleveland 2011) The connection to 
neurodegeneration exists with AR in Kennedy’s disease or spinal and bulbar muscular 
atrophy (SBMA). Death of motor neurons in the central nervous system caused by SBMA 
has been linked to inclusions of mutated AR. (Monks et al. 2008) 
 
There is some evidence that some cancers are related to TDP-43 and FUS. The study of 
Zeng et al. (2017) shows that TDP-43 is overexpressed and regulates cancer growth as 
well as metastasis in melanoma, skin cancer. TDP-43 promotes the survival of glioblas-
toma, a type of brain cancer (Chang & Lin 2014). In neuroblastoma, a type of nerve tis-
sue cancer, and in breast cancer, high TDP-43 expression together with a tumour sup-
pressor, tripartite motif-containing protein 16 (TRIM16), inhibits cancer growth. (Kim 
et al. 2016). 
  
According to Shing et al. (2003), FUS gene fusions with erythroblast transformation-
specific (ETS) related gene (ERG) are related to rare cases of myeloid leukaemia, bone 
marrow cancer. Similarly, fusions of FUS and the fifth Ewing variant (FEV) gene are 
present in sarcomas, cancers of connective tissue (Ng et al. 2007). FUS has also been 
linked to regulation of breast cancer, with FUS down-regulation and interaction with 
other cancer suppressing factors leading to cancer cell death (Ke et al. 2016).  
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Based on a study of Brooke et al. (2011), FUS is down-regulated by androgens and a 
mediator of androgen signalling and prostate cancer progression. FUS has been found to 
be a co-activator of AR in prostate cancer cells, where it enhances AR transcriptional 
activity (Haile et al. 2011). 
 
 
2.3 Methods of Protein Research 
 
Proteomic methods are concerned with obtaining proteins from various complex biolog-
ical samples and enabling their analysis. Proteomics faces the challenge of assessing the 
significance, function, interaction and structural variation of these diverse biomolecules. 
Reflecting the complicated nature of proteomic mechanics, numerous research methods 
exist and they are under constant development. In this chapter, a brief look into some 
examples of frequently applied methods will be provided. 
 
Total protein concentration is determined with spectrophotometric techniques such as 
Lowry and Bradford protein assays. High-performance liquid chromatography (HPLC) 
and liquid chromatography-mass spectrometry (LC-MS) can detect the presence and 
amount of a specific protein automatedly. Antibody-based immunoassays such as en-
zyme-linked immunosorbent assay (ELISA), immunoprecipitation (IP) and Western 
Blotting are used to detect the presence, concentration as well as interactions of proteins.  
 
The field of proteomics can be divided roughly into the six areas of expression profiling, 
modification research, protein-protein interactions, structure studies, functional prote-
omics and proteome mining. Functional proteomics refers to the study of target proteins 
instead of complete proteomes. Proteome mining searches for possible drug targets 
(Graves & Haystead 2002) 
 
To assess which proteins are present in a sample, the proteins have to be rendered into an 
analysable state. Studying proteomics involves extracting the proteins of interest from 
samples, purification with column chromatography and separation with electrophoresis. 
Further analysis and choice of methods is highly varied depending on the viewpoint. 
(Graves & Haystead 2002)  
 
19 
 
Proteins have to be released from biological sample material, usually by homogenisation 
of the sample by for example sonication and centrifugation, and using buffers that lyse 
the cell membranes. Purification removes contaminants with column chromatography, 
which can be for example size-exclusion, affinity, ion-exchange or HPLC. Reverse Phase 
HPLC is the method of choice for uncharged molecules and often used in proteomics. 
(Campbell & Farrell 2012, 117) 
 
The traditional method of protein separation is gel electrophoresis. It is based on the prin-
ciple of charged molecules moving towards the oppositely charged electrode of an electric 
field. A charge is applied to proteins that is proportional to their molecular size. The 
movement of a protein in a gel placed in an electric field is relative to its size as a result. 
Electrophoresis is used to separate the proteins present in a sample according to their 
molecular sizes for further analysis. (Rabilloud, Chevallet, Luche & Lelong 2010) 
 
In sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE), proteins of 
interest are denatured and given a charge relative to size by SDS. In native electrophore-
sis, proteins are separated in their native form. In proteomic research this is used when a 
protein needs to be studied in its natural conformation. (Campbell & Farrell 2012, 126) 
 
Isoelectric focusing (IEF) is electrophoresis which takes advantage of the isoelectric 
points (pI) of proteins. At various pH values, proteins have different charges according 
to their pI value. In IEF, a pH gradient is applied in the separating gel placed in the electric 
field. This way, proteins traveling along the gel will generate a charge, become neutral 
when the pH equals their pI and become immobilised in a characteristic way. (Pergande 
& Cologna 2017) 
 
Two-dimensional gel electrophoresis (2-DE) combines SDS-PAGE and IEF. In 2-DE 
proteins are separated along first by their pI into one direction and secondly according to 
their size into another direction. (Adams and Gallagher 2004) The advantage of 2-DE is 
that post-translational modifications (PTMs) can be studied with it. Modifications to pro-
tein structure cause changes in the charge and mass of the protein. These changes affect 
the 2-DE migration pattern of proteins. Another advantage is use in expression profiling. 
The presence or absence of protein spots on 2-DE gels enables quantitative and qualitative 
comparison between protein samples. (Graves & Haystead 2002) 
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Some methods aim to determining the identity of a protein by assessing its primary struc-
ture, the amino acid sequence. Usually the first step is to hydrolyse the separated protein 
and to identify and quantify all the amino acids present in it. Automated amino acid ana-
lysers with HPLC are frequently used. Finally, the protein is fragmented into smaller parts 
to enable sequence determination with Edman degradation. The protein is degraded step-
wise starting at the amino-terminal. (Weder & Belitz 2003, 4807) 
 
Mass spectrometry (MS) techniques are used to determine amino acid sequences of pro-
teins. MS methods provide good sensitivity, low limits of detection, high throughput and 
the ability to analyse complex mixtures of proteins. Protein identity of individual, prote-
olysed 2-DE bands is provided by mass finger printing analysis combined with peptide 
sequencing. (Andersen & Mann 2000)  
 
Tandem mass spectrometry (MS/MS) techniques provide the ability to identify proteins 
from complex samples through fragmentation data. Proteins separated from complex 
sample matrices can be analysed with for example a quadrupole ion trap MS/MS. MS/MS 
counts the peptide mass, fragments the peptides and determines the resulting ion frag-
ments. Identification is based on characteristic fragmentation fingerprint data, with the 
use of algorithms that search databases for identity. (Graves & Haystead 2002) 
 
Modern methods applied to study the proteome usually involve shotgun (bottom-up) pro-
teome analysis, where all amino acids in a protein mixture are determined. In contrast, in 
a top-down proteomics method, whole intact proteins can be studied. Middle-down anal-
ysis combines bottom-up and top-down techniques to provide a wider capability of rec-
ognizing proteins. In shotgun proteomics analysis, peptides in a protein mixture are re-
leased by proteolysis, fractionated and analysed by liquid chromatography tandem mass 
spectrometry (LC-MS/MS). (Zhang et. al 2013)  
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2.3.1 Immunological Methods  
 
Immunological protein analytics function on the principle of antibody-antigen interaction. 
Antibodies or immunoglobulins are proteins produced by the immune system. Antigens 
are proteins that activate immune reactions. They are present for example on the surface 
of pathogens that cause illness. Antibodies recognise and bind to antigens by a specific 
site, the epitope, present on the surface of the antigen. This enables the targeting and 
neutralisation of pathogens. (Campbell & Farrell 2012, 411) 
 
The antibody-antigen interaction can be utilised to recognise proteins. Specifically de-
signed antibodies bind to the epitope of the protein of interest. The detection of proteins 
with antibodies is referred to as immunodetection. Western Blotting, or immunoblotting, 
is a method that is used to study relative levels of proteins in biological samples. It in-
volves separation of proteins with SDS-PAGE from sample lysates. Following separation, 
the proteins are transferred onto a solid support membrane that allows immunodetection. 
(Whitford 2005, 337–339) 
 
Immunodetection is performed with primary antibodies that bind to the protein and sec-
ondary antibodies that bind to the primary antibody to enhance signal. The secondary 
antibody usually is conjugated with a molecule that allows detection. The most common 
detection methods are fluorescent and enzymatic. Enzymatic methods, where a substrate 
such as horseradish peroxide (HRP) is conjugated to the secondary antibody, include col-
orimetric, colour-producing, and chemiluminescent, light-producing, reactions. (Whit-
ford 2005, 337–339) 
 
 
2.3.2 Protein Expression Experiments 
 
Expression of genes at the right level at the correct developmental stage of an organism 
is vital for the function of the organism. Several molecular mechanisms work together to 
regulate genes so that they are only active when appropriate. Too much or too little ex-
pression of a gene can be detrimental to the organism. Proteins are coded for by genes 
through mRNA to mediate gene function, and expressed as required in response to various 
stimuli. Protein expression experiments are used to study how altering the levels of certain 
proteins affects cellular mechanisms. (Gregory 2012) 
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The genes responsible for the proteins are manipulated at gene level to induce expression 
changes. Exploiting overexpression, causing a specific gene to overproduce its gene prod-
uct, and assessing the following changes, allows studying various pathways and molecu-
lar mechanisms. Overexpression can be achieved with specifically designed plasmid vec-
tors containing an insert that expresses the gene coding for the protein. (Douglas et al. 
2012) Gene silencing in turn can be achieved with RNA interference (RNAi) (Heino & 
Vuento 2017, 78). 
 
Ribonucleic acid interference (RNAi) is a method to induce sequence specific gene si-
lencing. It is a cellular defence mechanism and developmental gene regulation mecha-
nism in eukaryotes. It is activated for example when exogenous genetic material (DNA 
or viral RNA) enters a cell. In gene technology, siRNA constructs are designed to bind to 
and degrade specific mRNA targets, prevent their function and induce gene silencing. 
(Wilson & Doudna 2013) 
 
RNAi occurs through small noncoding RNAs (small ncRNAs), including microRNAs 
(miRNAs) and small interfering RNAs (siRNAs), 20 to 30 nucleotides long RNAs that 
regulate gene expression. The function of small ncRNAs is to direct the action of Argo-
naute family effector proteins to specific sequences in the targeted genetic material. Ar-
gonaute proteins are enzymes, mostly endonucleases, that catalyse the cleavage of mole-
cules. (Carthew & Sontheimer 2009) 
 
siRNAs are formed from foreign genetic material such as viral DNA, in contrast to miR-
NAs which originate in the host genome. In the siRNA pathway, a complex containing 
the RNase III enzyme Drosha processes the foreign double-stranded DNA (dsDNA) ma-
terial in the nucleus into double-stranded siRNAs. The products are released into the cy-
toplasm, where the double-stranded siRNAs are cleaved by Dicer, an endoribonuclease 
enzyme. (Shabalina & Koonin 2008) 
 
The following elimination process occurs by degradation through the RNA-induced si-
lencing complex (RISC). The complex is formed by an Argonaute protein and one strand 
of the siRNA working as the recognition template in the cytoplasm. The sequence of the 
siRNA will convey specificity for the foreign mRNA and direct the Argonaute protein to 
degrade it. (Liu et al. 2004)  
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Transfections are used to introduce the silencing and overexpression inducing constructs 
into mammalian cells. Biological, chemical and physical methods can be applied to de-
liver the genetic material into cells. Biological methods include using viruses, chemical 
methods cationic polymers and physical methods electroporation. Transfections can be 
either transient, temporary, or stable, long-lasting, depending on the duration of the effect 
on gene function. (Kim & Eberwine 2010) 
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3 AIMS OF THE STUDY 
 
 
The purpose of this thesis is to determine how changing the levels of TDP-43, FUS and 
AR proteins alters the levels of each other individual protein. This will improve under-
standing of protein level mechanics of these proteins in prostate cancer and test hypothe-
ses formed from previous research. Determining whether the inter-regulation shows any 
difference with sample AR status helps reveal if these proteins are related to the formation 
of castration resistance. 
 
The objective is to provide a preliminary study of the inter-regulation of TDP-43 and FUS 
and how it is related to AR. The objective is also to test the required experimental meth-
ods, protocols and reagents, such as the siRNA constructs and overexpression plasmids. 
Further studies into the subject by the research group will benefit from this study and use 
the results to plan further experiments. 
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4 MATERIALS AND METHODS 
 
 
4.1 Cell Culture 
 
Cell lines used in this study were PC-3 and LNCaP, two lines commonly used in prostate 
cancer research. PC-3 cells are adherent tumorigenic epithelial cells acquired from a pros-
tate cancer bone metastasis. PC-3 cells lack AR expression and are metastatic. (ATCC 
2016)  
 
In this study, PC-3 cells were used to model prostate cancer cells with low AR expression. 
PC-3 cells were cultured in Ham’s F-12K medium (Lonza) supplemented with L-Gluta-
mine, fetal bovine serum (FBS) and penicillin-streptomycin in humidified incubators at 
37 ℃, 5 % COଶ. Picture 1 shows PC-3 cells cultured during the experiments. 
 
 
PICTURE 1. PC-3 cells in culture  
 
Lymph node carcinoma of the prostate (LNCaP) cells are derived from a prostate cancer 
metastasis of a lymph node. These cells have stable AR expression, are very androgen 
sensitive and have very low metastatic ability. (ATCC 2016) LNCaP cells express an AR 
amplification present in prostate cancer cells after ADT, the T877A mutation (Brooke et 
al. 2015).A cell culture of LNCaP used in the study is shown in Picture 2. 
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PICTURE 2. LNCaP cells in culture 
 
LNCaP cells were used in this study to model CRPC with high AR expression. LNCaP 
cells were cultured in RPMI 1640 medium (Gibco) supplemented with L-Glutamine, FBS 
and penicillin-streptomycin in humidified incubators at 37 ℃, 5 % COଶ. 
 
 
4.2 Transfections 
 
The proteins TDP-43, FUS and AR were removed from the sample cells with siRNA 
induced RNAi of the genes producing the proteins, and overexpressed with overexpres-
sion plasmids. The siRNA constructs used for transfections were Thermo Fisher Scien-
tific Silencer Select constructs that are described in Table 1. The negative siRNA control 
was Thermo Fisher Scientific Silencer Select Negative Control No. 1 siRNA. AR silenc-
ing was performed only to the AR expressing LNCaP cells. 
 
TABLE 1. Thermo Fisher Scientific Silencer Select constructs used in siRNA transfec-
tions 
Protein siRNA 1 siRNA 2 
AR s1539 s1538 
FUS s5401 s5403 
TDP-43 s23829 s23830 
 
For the overexpression transfections, TDP-43 and FUS plasmids were ordered from the 
Addgene plasmid repository. TAR DBP overexpression was induced with TDP43 NO-
TAG1, plasmid number 28206 gifted by Zuoshang Xu and published by Yang et al. 
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(2010). FUS overexpressions were carried out with Addgene plasmid number 21828, TLS 
2: hTLS.pCDNA1 gifted by David Ron, introduced by Crozat, Aman, Mandahl & Ron 
(1993). AR overexpression was performed to the PC-3 cells with low AR expression. 
Overexpression was induced with the pcDNA 3.1 (+) plasmid (Invitrogen) with an AR 
insert, published by Waltering et al. (2009). The empty control was the pcDNA 3.1 (+) 
plasmid without an insert. 
 
The plasmids for TDP-43 and FUS were received as agar stabs. They were transformed 
into Escherichia coli strains under antibiotic selection with ampicillin and incubated over-
night with constant shaking. The plasmids were extracted with Nucleospin Plasmid Sep-
aration and a NucleoBond Xtra Midi/Maxi Extraction kits (Macherey-Nagel) according 
to the manufacturer’s protocols. Their concentration, purity and identity were confirmed 
with a Nanodrop 2000 spectrophotometer unit (Thermo Fisher Scientific) and restriction 
enzyme digestion.  
 
Transfections were carried out using the transfection reagents INTERFERin for silencing 
and JetPEI PolyPlus for overexpression (PolyPlus-Transfection SA) according to the 
manufacturer’s protocol. Cells were seeded onto nine cell culture dishes per experiment, 
one for each protein to be affected, two non-treated controls and the negative controls. 
The number of cells seeded for transfection per dish was 1,5 ∙ 10଺ for LNCaP and 8 ∙ 10ହ 
for PC-3. Cell densities were determined using Luna cell counting haemocytometer slides 
and a Luna II automated cell counter unit (Logos Biosystems).  
 
Transfections were performed on the same day according to the reverse transfection pro-
tocol. The siRNA constructs or plasmids were diluted into Opti-MEM (Gibco). INTER-
FERin or jetPEI reagent was added and the mixture incubated for 10 minutes for INTER-
FERin and 15 minutes for jetPEI to allow complex formation. The transfection complexes 
were added onto the cells. The cultures were incubated at 37 ℃ until the cells had 
achieved sufficient growth. 
 
 
4.3 Preparation of Protein Lysates 
 
After incubation, the cells were collected by scraping and pelleted by centrifugation. The 
required amount of triton lysis buffer according to pellet size (200 µl for PC-3 and 400 µl 
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for LNCaP) was supplemented with 10 μl per ml 25x protease inhibitor cocktail (Roche), 
10 μl per ml 0,1 ୫୭୪
୪
 DTT and 5 μl per ml 0,2 ୫୭୪
୪
 PMSF. The lysis buffer solution was added 
onto the pellets and allowed 30 minutes incubation on ice. The lysates were sonicated 
with a Bioruptor Ultrasonicator (Diagenode) four times for 30 seconds on high power, 
centrifuged at 16000 g for 10 minutes and the supernatant was gathered. 
 
Protein concentrations of the lysates were determined with a Detergent Compatible (DC) 
colorimetric Protein Assay kit (Bio-Rad) on a 96-well plate using five sample replicates. 
A bovine serum albumin (BSA) standard series with concentrations from 1 to 2 ୫୥
୫୪
 was 
used. The colorimetric reaction was measured spectrophotometrically at 690 nm using 
an EnVision 2105 Multimode Plate Reader unit (Perkin Elmer). Protein concentrations 
were determined by linear regression from a standard curve using Microsoft Excel soft-
ware. 
 
 
4.4 Western Blotting 
 
Relative levels of AR, FUS, and TDP-43 following transfections were determined with 
Western Blotting. Aconitase 2 (ACO2) and pan-actin, house-keeping genes expressed at 
the same level in all cells, were used as the load controls. Molecular sizes of the proteins 
and the antibodies (Ab) used for their detection are shown in Table 2.  
 
TABLE 2. Molecular sizes of the proteins (kDa) and antibodies 
Protein Size (kDa) Primary Ab Secondary Ab 
AR 99 AR monoclonal Ab 441 (mouse) 0,3 µg/µl (SCBT) rabbit-anti-mouse-HRP  
TDP-43 44,7 TARDBP Ab ARP38942_T100 (rabbit) 1:2000 (Aviva Biosystems) swine-anti-rabbit-HRP 
FUS 53 FUS/TLS Ab 4H11 (mouse) 1:200 (SCBT) rabbit-anti-mouse-HRP 
ACO2 85 Anti-ACO2 Ab (rabbit) 1:1000 (Sigma Aldrich) swine-anti-rabbit-HRP 
pan-actin 42 pan-actin Ab (mouse) 1:1000 (Ne-omarkers) rabbit-anti-mouse-HRP 
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Proteins were separated with sodium dodecyl sulphate polyacrylamide gel electrophoresis 
(SDS-PAGE). 20 μg of protein was loaded per lane. Color Prestained Protein Standard 
Broad Range ladder (New England Biolabs) was used for size standardization. The pro-
teins were transferred to an Immobilon P PVDF membrane (Merck Millipore). After 
transfer, immunodetection was performed according to the incubation protocol described 
in Table 3. All secondary antibodies (Dako) were diluted to 1: 5000. 
 
TABLE 3. Immunodetection incubation protocol 
Step Reagent  Incubation time 
Rinse 1x TBS  5 min 
Blocking 3 % BSA in 1x TBS  1 hour / overnight at 4 ℃ 
Primary probe 
Primary Ab in 1x TBS + 1% 
BSA + 0.01% NaNଷ 
 1 hour / overnight at 4 ℃ 
Wash 1 1x TBS  5 min 
Wash 2 0.1 % Tween-20 in 1x TBS  3x 10 min 
Wash 3 1x TBS  5 min 
Secondary probe Secondary Ab in 1 % BSA  30 min to 1 hour 
Wash 1 1x TBS  5 min 
Wash 2 0.1 % Tween-20 in 1x TBS  3x 10 min 
Wash 3 1x TBS  5 min 
 
A Clarity Western Enhanced Chemiluminescence (ECL) kit (Bio-Rad), that utilises the 
horseradish peroxide (HRP)-luminol system, was used for visualization with autoradiog-
raphy. The membrane was imaged using Kodak BioMax Cassettes, FujiFilm Medical X-
ray film 100NIF Super RX and an AGFA CP-1000 Automatic X-Ray Film Processor 
unit. 
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5 RESULTS 
 
 
5.1 siRNA Experiments 
 
The genes responsible for TDP-43, FUS and AR were silenced with siRNA transfections 
in two experiments. All siRNA constructs were functional, and FUS level was decreased 
by AR silencing in LNCaP. The results are shown in figure 5. 
 
 
FIGURE 5. siRNA transfection results. Abbreviations: N-T: non-treated control, si-ctrl: 
the negative control siRNA, siAR: AR knockdown, siFUS: FUS knockdown and siTDP-
43: TARDBP knockdown. 
 
The observed bands were compared to the siRNA control bands to estimate changes in 
band strength. The targeted genes were silenced and their corresponding protein products 
absent from the cells as shown by missing bands. FUS and TDP-43 bands were missing 
or significantly reduced at their corresponding siRNA lanes. PC-3 normally exhibits no 
AR expression, so all PC-3 lanes showed no AR bands. The AR band was missing in the 
LNCaP siAR lane.  
 
In the second experiment, shown on the right in figure 5, some technical difficulties were 
encountered. The LNCaP siAR lane was loaded with less protein because the concentra-
tion was very low. The PC-3 siTDP-43 well leaked and most of the loaded protein was 
lost. The results from these lanes are therefore unreliable. The load control results show 
that some protein was present. The exact amount is however unknown, so the results are 
not eligible. PC-3 load control bands are thicker, this can be due to uneven loading but 
also the high actin protein content of PC-3 cells. 
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5.2 Overexpression Experiments 
 
The proteins TDP-43, FUS and AR were overexpressed with plasmid transfections in two 
experiments. AR and FUS overexpression plasmids were confirmed to work as intended. 
The function of the TDP-43 plasmid could not be confirmed. The results are shown in 
figure 6. 
 
 
FIGURE 6. Overexpression transfection results. Abbreviations: N-T: non-treated control, 
oe-ctrl: the negative control plasmid, oeAR: AR overexpression, oeFUS: FUS overex-
pression and oeTDP-43: TDP-43 overexpression. 
 
The AR band was missing from all PC-3 lanes as expected. A possible increase can be 
seen in the PC-3 oeAR lane of the first experiment. In the second experiment PC-3 oeAR 
clearly shows an AR band. In the first experiment oeFUS lanes showed thicker bands, but 
not in the second experiment. TDP-43 was not reliably increased in either experiment. 
The LNCaP oeTDP-43 lane shows some increase compared to other bands.  
 
Load volumes were even except for the first PC-3 N-T control lane, which had received 
slightly less protein as shown by a thinner band. The PC-3 sample lanes showed thicker 
bands in the second experiment. The FUS control lanes of the second experiment unex-
pectedly showed thinner bands, which sometimes occurs in transfections. There was a lot 
of interference for AR in the first experiment (left in figure 6) and for TDP-43 in the 
second one (right in figure 6). Because of this, it is challenging to interpret the results 
from these lanes.  
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6 DISCUSSION 
 
 
In this thesis, one objective was to test the protocols and reagents used in the study. The 
siRNA constructs and antibodies were all confirmed to work, and the protocols required 
for the expression experiments were functional. FUS and AR overexpression plasmids 
were working as intended, but the function of the TDP-43 plasmid could not be con-
firmed.  
 
The main purpose of the study was to assess how changing the levels of TDP-43, FUS or 
AR would affect the other proteins in cell lines with high AR expression, LNCaP, and 
low AR expression, PC-3. The experiments showed promising preliminary biological re-
sults. In the first siRNA experiment, the band for FUS was also fainter in the LNCaP 
siAR lane, which suggests that knocking down AR might lower FUS levels. 
 
The results showed down-regulation of FUS when TAR DBP is silenced in LNCaP, but 
not in PC-3 cells. A slight decrease in the strength of the FUS band in the LNCaP siTDP-
43 lane was seen in both siRNA experiments. As for PC-3, the siTDP-43 lane FUS band 
showed no change in strength in the first experiment. These results suggest that silencing 
TAR DBP in the presence of AR could lead to FUS down-regulation. LNCaP cells which 
represented CRPC in this study have high AR expression, whereas PC-3 cells represent-
ing prostate cancer before hormonal treatment have low AR expression. A change in only 
LNCaP FUS levels suggests that the observed downregulation could be tied to the AR 
status of the samples. 
 
In a previous study (Latonen et al. 2018), primary prostate cancer samples with low AR 
expression and CPRC samples with high AR expression were grouped by their protein 
level expression data of TDP-43 and FUS. TDP-43 and FUS expression levels had a neg-
ative correlation separating the groups. The results showing FUS downregulation by 
TDP-43 silencing only in AR expressing cells point to some AR related inter-regulation 
being present. No confirmed change was observed in TDP-43 or AR levels following the 
other knockdowns in PC-3. A very slight decrease in AR level and a slight increase in 
TDP-43 level could be seen when FUS was knocked down in LNCaP.  
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Down-regulation of FUS by androgens and FUS mediating androgen signalling has been 
reported (Brooke et al. 2011). FUS has also been shown to be a co-activator of AR in 
prostate cancer cells, enhancing AR transcriptional activity (Haile et al. 2011). These pre-
vious studies suggest an interaction between AR and FUS. The results of this thesis sug-
gest some connection does exist. The connection of TDP-43 and AR has not been studied 
earlier. TDP-43 and FUS have been connected in neurodegeneration (Hanson et al. 2012), 
pointing that they might have a connection.  
 
The overexpression experiments proved more challenging. The TDP-43 overexpressions 
were not successful. Overexpressing AR in PC-3 lead to a slight increase in TDP-43 level 
in the second experiment. FUS overexpression lead to a very slight TDP-43 increase in 
LNCaP in one experiment. An increase of the same weight in TDP-43 can possibly be 
seen in the second PC-3 oeFUS. 
 
With alterations this small in band strength and with no confirmation by multiple repeats 
due to technical challenges and time limits, the results require more testing. It should be 
noted that many more repeats than two are required to validate these results. The results 
present important starting points for further experimentation. 
 
In the last siRNA experiment, the siTDP-43 lane was near empty due to well leak, so the 
experiment has to be repeated for confirmation. The LNCaP siAR lane received less pro-
tein than the other lanes in the same experiment. Especially FUS downregulation resulting 
from AR silencing should be investigated in further experiments. There was a lot of in-
terference in the AR and TDP-43 lanes in some of the overexpression blots and it is dif-
ficult to judge the exact weight of the bands. 
 
Considerable time was invested in learning and practicing the methods, as Western Blot-
ting is a time-consuming multi-step technique that can prove challenging. Cell cultures 
had to be established and allowed to achieve adept growth for transfections. The cells 
used in the second experiments were slower to grow, which caused delay. Further repeats 
of the experiments are required to investigate whether the results achieved in this study 
are reliable. 
 
The technical difficulties were related to cell growth, protein yield and SDS-PAGE load-
ing. Transfections cause damage to cells and can cause their growth rate to slow down. 
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Transfected cells should be regularly examined under the microscope to determine if they 
can be gathered. Enough time must be allowed for them to grow before gathering. Col-
lected too early on, they will not yield enough cellular material and protein for Western 
Blotting. However, transient transfections were used, so their effects will cease with too 
much time, so collection timing is vital. 
 
The observed unreliability of the TDP-43 plasmid could be due to multiple reasons. 
Transfection efficiency cannot be easily predicted and inexperience can easily cause fail-
ure. Success of the other plasmids suggests however that the plasmid itself could be non-
functional. This can be explained by the plasmid not targeting the TARDBP sequence as 
intended, or an unexpected mechanism occurring during transcription or translation of 
TDP-43. The plasmid should be tested with for example DNA sequencing to further en-
sure its functionality. 
 
Gene sequences can vary to some extent in cells (Latonen 2018), which could explain 
why the plasmid does not function as expected.  The function of another TDP-43 overex-
pression plasmid could be tested with the same experiment. Explanations at RNA or pro-
tein level could be the formation of a protein product that was not recognised by the TDP-
43 antibody. This could be due to alternative splicing and translational modifications of 
TDP-43. Cells used in the second experiments were from another origin. As cell cultures 
can withstand only a certain number of passages, new cells had to be provided after initial 
testing and the first experiments. The change of cells should also be considered when 
judging the results, as cells of different origin can have slightly different qualities. 
 
Overexpression transfection experiments can be hard to accomplish, so the reason could 
simply be a failed transfection. Poor cell growth was seen in some cultures after transfec-
tion, and allowing for a day or two more growth time for the cells might have improved 
the results. Allowing cell growth permits the effects of transfections to take place, and the 
accumulation of cellular material and protein needed for Western Blotting. Transfection 
efficiency also varies unexpectedly with experiment and cell culture. 
 
Western Blotting and autoradiography can also cause challenge in interpreting the results. 
Antibodies and luminol reagents used in autoradiography lose their effectiveness over 
time, causing poor signal. Using fresh reagents or strengthening existing ones is important 
for success. Bacterial contamination of antibodies, membranes and blocking reagents can 
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cause interference that makes blots difficult to read. All reagents need to be stored in low 
temperature and new ones prepared as required. Adjusting exposure times in autoradiog-
raphy can be challenging if some bands show strong and some poor signal. Appropriate 
washing is key in Western Blotting to prevent background interference from unnecessary 
bands. 
 
Interpreting the results requires experience with Western Blotting. It can be challenging 
to reliably determine if a slight change in band strength is present, especially from con-
sequent scans of the x-rays. The bands need to be compared to the control lanes and the 
load control bands. Based on all this it needs to be judged if band strength variation is 
caused by uneven loading, exposure time or actual protein level changes. Very small var-
iations are challenging to judge in an objective way. 
 
The possible biological results of the experiments create guidelines for what to look for 
in the next experiments, where all tests should be repeated. Especially the partially failed 
LNCaP siAR and PC-3 siTDP-43 experiments need further assessment. Particular interest 
should be invested in further testing if knocking down AR lowers FUS levels, and if the 
down-regulation of FUS occurs when TAR DBP is silenced in LNCaP. RNA levels should 
also be determined to investigate the results as well as the failures. For example, assessing 
if silencing or overexpression has occurred on the RNA level when it has failed on the 
protein level could help understand where the problem lies. 
 
Silencing AR in LNCaP caused FUS to decrease. In turn, AR overexpression in PC-3 
caused TDP-43 to increase. These results oppose each other regarding AR and, if they 
can be confirmed, provide a hypothesis to continue from. They suggest that inter-regula-
tion into opposite directions could exist and that it could be related to AR status and 
changing it. This is in line with the findings that TDP-43 and FUS have a negative corre-
lation at the protein level (Latonen 2017). Also, TDP-43 decreasing with siFUS in only 
LNCaP points at AR having a significance in the inter-regulation of these proteins. 
 
AR status of prostate cancer is altered when castration resistance develops. CRPC cells 
have high AR expression and can possibly synthesise AR independently. (Lonergan & 
Tindell 2012) By determining changes in protein level of certain proteins, such as TDP-
43 and FUS, how they interact and how they are affected by AR, mechanisms of CRPC 
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could be elucidated. If AR was found to be reduced by affecting the proteins, new drug 
action targets to suppress AR might be developed. 
This thesis is a preliminary look into the inter-regulation of TDP-43, FUS and AR in 
prostate cancer cells, and helps continue research into the subject. With further assess-
ment, the inter-regulation of TDP-43 and FUS in relation to AR in prostate cancer, as 
well as the significance of this interaction to cancer development, can be better under-
stood. 
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